Ranibizumab Biosimilars in Treating Retinal Disorders: A Cost-Effective Revolution?

References

• Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106–e116. doi:10.1016/S2214-109X(13)70145-1
   PubMed Web of Science ®Google Scholar
• Schultz NM, Bhardwaj S, Barclay C, Gaspar L, Schwartz J. Global burden of dry age-related macular degeneration: a targeted literature review. Clin Ther. 2021;43(10):1792–1818. doi:10.1016/j.clinthera.2021.08.011
   PubMed Web of Science ®Google Scholar
• Holz FG, Oleksy P, Ricci F, Kaiser PK, Kiefer J, Schmitz-Valckenberg S. Efficacy and safety of biosimilar FYB201 compared with ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2022;129(1):54–63. doi:10.1016/j.ophtha.2021.04.031
   PubMed Web of Science ®Google Scholar
• Spooner K, Mhlanga C, Hong T, Broadhead G, Chang A. The burden of neovascular age-related macular degeneration: a patient’s perspective. Clin Ophthalmol. 2018;12:2483–2491. doi:10.2147/OPTH.S185052
   PubMed Web of Science ®Google Scholar
• Woo SJ, Veith M, Hamouz J, et al. Efficacy and safety of a proposed ranibizumab biosimilar product vs a reference ranibizumab product for patients with neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmol. 2021;139(1):68. doi:10.1001/jamaophthalmol.2020.5053
   PubMed Web of Science ®Google Scholar
• Blick SKA, Keating GM, Wagstaff AJ. Ranibizumab. Drugs. 2007;67(8):1199–1206. doi:10.2165/00003495-200767080-00007
   PubMed Web of Science ®Google Scholar
• Han F, Chen Han C, Han F. Profile of ranibizumab: efficacy and safety for the treatment of wet age-related macular degeneration. Ther Clin Risk Manag. 2012;343. doi:10.2147/TCRM.S32801
   PubMed Web of Science ®Google Scholar
• Vulto AG, Jaquez OA. The process defines the product: what really matters in biosimilar design and production? Rheumatology. 2017;56(suppl_4):iv14–iv29. doi:10.1093/rheumatology/kex278
   PubMed Web of Science ®Google Scholar
• Sharma A, Hafeez Faridi M, Kumar N, et al. Immunogenicity and efficacy after switching from original ranibizumab to a ranibizumab biosimilar: real-world data. Eye. 2020;34(6):1008–1009. doi:10.1038/s41433-019-0745-z
   PubMed Web of Science ®Google Scholar
• Sharma S, Khan M, Chaturvedi A; RE-ENACT 2 Study Investigators Group. A Multicenter, Retrospective Study (RE-ENACT 2) on the use of razumabTM (world’s first biosimilar ranibizumab) in wet age-related macular degeneration. Ophthalmol Ther. 2020;9(1):103–114. doi:10.1007/s40123-019-00228-7
   PubMed Web of Science ®Google Scholar
• Kirchhoff CF, Wang XM, Conlon HD, Anderson S, Ryan AM, Bose A. Biosimilars: key regulatory considerations and similarity assessment tools. Biotechnol Bioeng. 2017;114(12):2696–2705. doi:10.1002/bit.26438
   PubMed Web of Science ®Google Scholar
• Honavar S. From biologics to biosimilars and biobetters - democratization of high-end therapeutics. Indian J Ophthalmol. 2021;69(2):207. doi:10.4103/ijo.IJO_150_21
   PubMed Web of Science ®Google Scholar
• Stanhope R, Sörgel F, Gravel P, Schuetz YBP, Zabransky M, Muenzberg M. Bioequivalence studies of omnitrope, the first biosimilar/rhGH follow‐on protein: two comparative phase 1 randomized studies and population pharmacokinetic analysis. J Clin Pharmacol. 2010;50(11):1339–1348. doi:10.1177/0091270009359005
   PubMed Web of Science ®Google Scholar
• Palmer BF, Clegg DJ. Oxygen sensing and metabolic homeostasis. Mol Cell Endocrinol. 2014;397(1–2):51–58. doi:10.1016/j.mce.2014.08.001
   PubMed Web of Science ®Google Scholar
• Lungu C, Mehedinti M. Molecular motifs in vascular morphogenesis: Vascular Endothelial Growth Factor A (VEGFA) as the leading promoter of angiogenesis. Int J Mol Sci. 2023;24(15):12169. doi:10.3390/ijms241512169
   PubMed Web of Science ®Google Scholar
• Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti–vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006;26(8):859–870. doi:10.1097/01.iae.0000242842.14624.e7
   PubMed Web of Science ®Google Scholar
• Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15(2):171–185. doi:10.1007/s10456-011-9249-6
   PubMed Web of Science ®Google Scholar
• Klettner A, Roider J. Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways. Invest Opthalmol Vis Sci. 2008;49(10):4523. doi:10.1167/iovs.08-2055
   PubMed Web of Science ®Google Scholar
• Xu L, Lu T, Tuomi L, et al. Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach. Invest Opthalmol Vis Sci. 2013;54(3):1616. doi:10.1167/iovs.12-10260
   PubMed Web of Science ®Google Scholar
• Singh R, Kaiser P. Role of ranibizumab in management of macular degeneration. Indian J Ophthalmol. 2007;55(6):421. doi:10.4103/0301-4738.36475
   PubMedGoogle Scholar
• Fidler M, Fleck BW, Stahl A, et al. Ranibizumab population pharmacokinetics and free VEGF pharmacodynamics in preterm infants with retinopathy of prematurity in the RAINBOW trial. Transl Vis Sci Technol. 2020;9(8):43. doi:10.1167/tvst.9.8.43
   PubMed Web of Science ®Google Scholar
• Sharma S, Khan MA, Chaturvedi A; RE-ENACT Study Investigators Group. Real-life clinical effectiveness of razumab® (the world’s first biosimilar of ranibizumab) in retinal vein occlusion: a subgroup analysis of the pooled Retrospective RE-ENACT Study. Ophthalmologica. 2019;241(1):24–31. doi:10.1159/000488602
   PubMed Web of Science ®Google Scholar
• Chakraborty D, Mondal S, Boral S, et al. Biosimilar versus InnovAtor MoLecule of RAnibizumab in neovascular age-related MaCular DEgeneration (The BALANCE Trial): real-world evidence. Clin Ophthalmol. 2023;17:1067–1076. doi:10.2147/OPTH.S407219
   PubMed Web of Science ®Google Scholar
• Apsangikar P, Ghadge P, Naik M, Nair S, Payghan R. Randomised, double-blind, comparative clinical study of new ranibizumab biosimilar in neovascular (Wet) age-related macular degeneration. Clin Ophthalmol. 2021;15:3087–3095. doi:10.2147/OPTH.S307746
   PubMed Web of Science ®Google Scholar
• Yoon CK, Oh J, Bae K, Park UC, Yu KS, Yu HG. Efficacy and safety of a new ranibizumab biosimilar CKD-701 using a pro re nata treatment regimen in neovascular age-related macular degeneration: a phase 3 randomized clinical trial. Vavvas DG, ed. PLoS One. 2022;17(11):e0275611. doi:10.1371/journal.pone.0275611
   PubMed Web of Science ®Google Scholar
• Loewenstein A, Czumbel N, Ernest J, Dusová J, Pearlman J, Nowosielska A. Randomized trial of biosimilar XSB-001 versus reference ranibizumab in patients with neovascular age-related macular degeneration. Ophthalmol Retina. 2023;7(9):753–761. doi:10.1016/j.oret.2023.05.005
   PubMedGoogle Scholar
• Singh R, Chauhan R, Saxena A, et al. A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of lupin’s ranibizumab with lucentis ® in patients with neovascular age-related macular degeneration. Indian J Ophthalmol. 2022;70(8):3008. doi:10.4103/ijo.IJO_2118_21
   PubMed Web of Science ®Google Scholar
• Prajapati V, Choudhary T, Chauhan W, et al. Efficacy of a biosimilar ranibizumab monotherapy for the treatment of retinopathy of prematurity. Indian J Ophthalmol. 2023;71(2):411. doi:10.4103/ijo.IJO_973_22
   PubMed Web of Science ®Google Scholar
• Chakraborty D, Sengupta S, Mondal S, et al. Comparison of innovator vs. biosimilar ranibizumab in treating diabetic macular edema: a Multicenter Retrospective Study. Ophthalmol Ther. 2022;11(2):629–638. doi:10.1007/s40123-022-00463-5
   PubMed Web of Science ®Google Scholar
• Soman M, Nair I, Sheth JU, Nair U. Innovator Versus Biosimilar Ranibizumab in Polypoidal Choroidal Vasculopathy: real-World Evidence. Ophthalmol Ther. 2022;11(3):1175–1186. doi:10.1007/s40123-022-00507-w
   PubMed Web of Science ®Google Scholar
• Ratra D, Roy K, Giridhar S, et al. Comparison between ranibizumab biosimilar, innovator ranibizumab and bevacizumab in a real-world situation. Ophthalmol Ther. 2022;11(1):135–149. doi:10.1007/s40123-021-00416-4
   PubMed Web of Science ®Google Scholar
• Ingrasciotta Y, Cutroneo PM, Marcianò I, Giezen T, Atzeni F, Trifirò G. Safety of biologics, including biosimilars: perspectives on current status and future direction. Drug Saf. 2018;41(11):1013–1022. doi:10.1007/s40264-018-0684-9
   PubMed Web of Science ®Google Scholar
• Hatamnejad A, Dadak R, Orr S, Wykoff C, Choudhry N. Systematic review of efficacy and meta-analysis of safety of ranibizumab biosimilars relative to reference ranibizumab anti-VEGF therapy for nAMD treatment. BMJ Open Ophthalmol. 2023;8(1):e001205. doi:10.1136/bmjophth-2022-001205
   PubMed Web of Science ®Google Scholar
• Bressler NM, Kim T, Oh I, Russo P, Kim MY, Woo SJ. Immunogenicity with ranibizumab biosimilar SB11 (byooviz) and reference product lucentis and association with efficacy, safety, and pharmacokinetics: a post hoc analysis of a phase 3 randomized clinical trial. JAMA Ophthalmol. 2023;141(2):117. doi:10.1001/jamaophthalmol.2022.5403
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA). Guideline on immunogenicity assessment of therapeutic proteins; 2017. Available rom: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-immunogenicity-assessment-therapeutic-proteins-revision-1_en.pdf. Accessed February 5, 2024.
   Google Scholar
• Kaiser PK, Schmitz-Valckenberg MS, Holz FG. Anti–vascular endothelial growth factor biosimilars in ophthalmology. Retina. 2022;42(12):2243–2250. doi:10.1097/IAE.0000000000003626
   PubMed Web of Science ®Google Scholar
• Jackson S, Stokes JP. Impact of out‐of‐pocket costs on patient initiation, adherence and persistence rates for patients treated with anti‐vascular endothelial growth factor medicines. Clin Experiment Ophthalmol. 2020;48(4):477–485. doi:10.1111/ceo.13706
   PubMed Web of Science ®Google Scholar
• Sharma A, Holz FG, Regillo CD, et al. Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER – survey). Expert Opin Biol Ther. 2023;23(8):851–859. doi:10.1080/14712598.2023.2176218
   PubMed Web of Science ®Google Scholar
• Yanagi Y, Takahashi K, Iida T, et al. Cost-effectiveness analysis of ranibizumab biosimilar for neovascular age-related macular degeneration in Japan. Ophthalmol Ther. 2023;12(4):2005–2021. Erratum in: Ophthalmol Ther. 2023 12(5):2821-2822. doi:10.1007/s40123-023-00715-y
   PubMed Web of Science ®Google Scholar